Investors Back Asceneuron To Rival Lilly In Alzheimer’s Oral Drug Class

 
• By Andrew McConaghie

The Switzerland-based company is ready to begin a Phase II study with a novel OGA inhibitor after raising $100m from a consortium of investors.

Tau Alzheimer's disease
Pathological phosphorylation of Tau proteins leads to disintegration of microtubuli in an axon and to aggregation of the tau proteins. • Source: Shutterstock

More from Business

More from Scrip